Cargando…

Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review

Gout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisaniello, Huai Leng, Fisher, Mark C., Farquhar, Hamish, Vargas-Santos, Ana Beatriz, Hill, Catherine L., Stamp, Lisa K., Gaffo, Angelo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080370/
https://www.ncbi.nlm.nih.gov/pubmed/33910619
http://dx.doi.org/10.1186/s13075-021-02416-y
_version_ 1783685409755103232
author Pisaniello, Huai Leng
Fisher, Mark C.
Farquhar, Hamish
Vargas-Santos, Ana Beatriz
Hill, Catherine L.
Stamp, Lisa K.
Gaffo, Angelo L.
author_facet Pisaniello, Huai Leng
Fisher, Mark C.
Farquhar, Hamish
Vargas-Santos, Ana Beatriz
Hill, Catherine L.
Stamp, Lisa K.
Gaffo, Angelo L.
author_sort Pisaniello, Huai Leng
collection PubMed
description Gout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3–5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m(2)), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and/or safety analysis stratified by renal function were reviewed—colchicine (n = 20), anakinra (n = 7), canakinumab (n = 1), NSAIDs (n = 3), and glucocorticoids (n = 2). A total of 58 studies reported these primary outcomes without renal function stratification—colchicine (n = 29), anakinra (n = 10), canakinumab (n = 6), rilonacept (n = 2), NSAIDs (n = 1), and glucocorticoids (n = 10). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of < 30 mL/min/1.73 m(2)). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02416-y.
format Online
Article
Text
id pubmed-8080370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80803702021-04-29 Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review Pisaniello, Huai Leng Fisher, Mark C. Farquhar, Hamish Vargas-Santos, Ana Beatriz Hill, Catherine L. Stamp, Lisa K. Gaffo, Angelo L. Arthritis Res Ther Review Gout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3–5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m(2)), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and/or safety analysis stratified by renal function were reviewed—colchicine (n = 20), anakinra (n = 7), canakinumab (n = 1), NSAIDs (n = 3), and glucocorticoids (n = 2). A total of 58 studies reported these primary outcomes without renal function stratification—colchicine (n = 29), anakinra (n = 10), canakinumab (n = 6), rilonacept (n = 2), NSAIDs (n = 1), and glucocorticoids (n = 10). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of < 30 mL/min/1.73 m(2)). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02416-y. BioMed Central 2021-04-28 2021 /pmc/articles/PMC8080370/ /pubmed/33910619 http://dx.doi.org/10.1186/s13075-021-02416-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Pisaniello, Huai Leng
Fisher, Mark C.
Farquhar, Hamish
Vargas-Santos, Ana Beatriz
Hill, Catherine L.
Stamp, Lisa K.
Gaffo, Angelo L.
Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title_full Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title_fullStr Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title_full_unstemmed Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title_short Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
title_sort efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a gout, hyperuricemia and crystal-associated disease network (g-can)-initiated literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080370/
https://www.ncbi.nlm.nih.gov/pubmed/33910619
http://dx.doi.org/10.1186/s13075-021-02416-y
work_keys_str_mv AT pisaniellohuaileng efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT fishermarkc efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT farquharhamish efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT vargassantosanabeatriz efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT hillcatherinel efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT stamplisak efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview
AT gaffoangelol efficacyandsafetyofgoutflareprophylaxisandtherapyuseinpeoplewithchronickidneydiseaseagouthyperuricemiaandcrystalassociateddiseasenetworkgcaninitiatedliteraturereview